- Previous Close
46.75 - Open
46.67 - Bid 45.83 x 400
- Ask 45.89 x 400
- Day's Range
45.62 - 47.39 - 52 Week Range
20.84 - 47.71 - Volume
791,288 - Avg. Volume
851,723 - Market Cap (intraday)
4.792B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
40.58 - EPS (TTM)
1.13 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
67.60
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
www.corcept.comRecent News: CORT
View More
Performance Overview: CORT
Trailing total returns as of 10/2/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CORT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CORT
View MoreValuation Measures
Market Cap
4.79B
Enterprise Value
4.32B
Trailing P/E
40.58
Forward P/E
25.38
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.92
Price/Book (mrq)
8.04
Enterprise Value/Revenue
7.59
Enterprise Value/EBITDA
33.56
Financial Highlights
Profitability and Income Statement
Profit Margin
22.12%
Return on Assets (ttm)
12.91%
Return on Equity (ttm)
24.75%
Revenue (ttm)
569.61M
Net Income Avi to Common (ttm)
124.96M
Diluted EPS (ttm)
1.13
Balance Sheet and Cash Flow
Total Cash (mrq)
473.16M
Total Debt/Equity (mrq)
0.95%
Levered Free Cash Flow (ttm)
124.42M
Research Analysis: CORT
View MoreCompany Insights: CORT
CORT does not have Company Insights
Research Reports: CORT
View MoreRaising target price to $49.00
CORCEPT THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $49.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $37.00
CORCEPT THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $37.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about CORT?
CORCEPT THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $36.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $36.00
CORCEPT THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $36.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target